Overview / Abstract: |
T-cell lymphoma is a rare but deadly hematologic malignancy that is difficult to diagnose and has limited treatment options. Join us for this 2021 update to gain expert perspectives on: - Differential diagnosis In addition, our expert faculty provide evidence-based advice regarding: Due to the high demand for this live webinar, we are pleased to offer 2 dates and times: Thursday, March 11, 2021 @ 12:00 PM EST Statement of Need: Each year, 74,240 new cases of non-Hodgkin lymphoma are diagnosed and 19,940 people die of the disease (ACS, 2020). Among these cases, 12% to 15% are classified as peripheral T-cell lymphomas (PTCL), which comprise more than 10 different T-cell lymphomas (Zain, 2020). The diagnosis of PTCL is challenging, and 26% are categorized as PTCL, not otherwise specified (PTCL-NOS). Prognosis is poor, with a 5-year overall survival of less than 30% (Zain, 2020). Other less common subtypes of TCL include anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma (ATL), angioimmunoblastic TCL, and cutaneous TCL (CTCL) (NCCN, 2020b). The most common CTCL subtype is mycosis fungoides (MF), which is generally indolent; however, because it frequently mimics symptoms associated with other skin conditions, it can be difficult to diagnose in its early stages. Over time, MF can spread across the skin; in advanced stages, it can demonstrate extracutaneous involvement, invading the lymph nodes, blood, or occasionally other organs (NCCN, 2020a). Some patients develop Sézary syndrome, a rare, aggressive form of MF that affects both the skin and peripheral blood. Furthermore, CTCL is often resistant to chemotherapy, and the treatment of patients with advanced disease remains challenging (Alpdogan et al, 2020). TARGET AUDIENCE Hematologist/oncologists, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with T-cell lymphoma (TCL). LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: 1.) Apply guideline recommendations for the differential diagnosis of TCL |
Expiration |
Mar 15, 2021 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
Format |
Live / Seminar, Online, Webinar / Webcast / Video |
Credits / Hours |
1.0 CME/NCPD, MOC, ILNA |
Accreditation |
ACCME, ANCC, ONCC, AANPCP |
Presenters / Authors / Faculty |
Steven M. Horwitz, MD (Chairperson) |
Activity Specialities / Related Topics |
Pharmacology, Oncology / Cancer / Radiation Therapy, Medication Safety, Hematology, Diagnosis / Assessment / Patient History, Adverse Drug Reactions / ADR |
Sponsors / Supporters / Grant Providers |
This activity is supported by independent educational grants from Kyowa Kirin and SeaGen. |
Keywords / Search Terms |
i3 Health T-cell lymphoma, TCL, oncology, hematology, CME, NCPD, CNE, MOC, ILNA, free CME, free NCPD, CNE, free CE, CE, i3 Health Free CE CME Seminar CE CME, lymphoma diagnosis, lymphoma cancer treatment, cutaneous lymphoma, lymphoma research, |
LIVE Activity Location Details |
Date(s)
i3 Health |